Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ALLG Window study of Acalbrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma.

Next Previous
Trial Profile

An ALLG Window study of Acalbrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Carmustine; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Melphalan; Oxaliplatin; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms WAMM

Most Recent Events

  • 12 Dec 2023 Results (n=44) assessing safety and efficacy of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft in Fit Patients with Treatment Naive Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 29 Nov 2023 According to an AstraZeneca media release, data from this study will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
  • 19 Mar 2021 Planned initiation date changed from 1 Oct 2019 to 7 Sep 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top